Showing 1681-1690 of 1732 results for "".
- FDA Approves Ofatumumab—First and Only Self-administered B-cell Therapy for Relapsing MShttps://practicalneurology.com/news/fda-approves-ofatumumab-first-and-only-self-administered-b-cell-therapy-for-relapsing-ms/2469358/The Food and Drug Administration (FDA) has approved ofatumumab (Kesimpta; Novartis) as an subcutaneous autoinjection for treatment of relapsing forms of multiple sclerosis (RS), including clinically isolated syndrome (CIS), relapsing-remitting disease (RRMS), and active secondary progressive MS (
- Enrollment Begins for Phase 1b Clinical Trial of T-cell Immunotherapy for Progressive Multiple Sclerosishttps://practicalneurology.com/news/enrollment-begins-for-phase-1b-clinical-trial-of-t-cell-immunotherapy-for-progressive-multiple-sclerosis/2469303/The first participant has been enrolled in a phase 1b study of the allogeneic EBV T-cell immunotherapy (ATA188; Atara Biotherapeutics, South San Francisco, CA), for individuals with progressive forms of multiple sclerosis (MS). Participants in clinical sites across the US and Australia
- Ozanimod, a New Oral Treatment for Relapsing Multiple Sclerosis, Now Availablehttps://practicalneurology.com/news/ozanimod-a-new-oral-treatment-for-relapsing-multiple-sclerosis-now-available/2469283/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, Princeton, NJ) for treatment of relapsing forms of multiple sclerosis (MS) on March 25, 2020. Ozanimod, 0.92 mg, is a new once-daily oral medication for adults with relapsing MS. Ozanimod
- FDA Approves Apomorphine Sublingual Film for Treatment of OFF Periods in Parkinson Diseasehttps://practicalneurology.com/news/fda-aproves-apomorphine-sublingual-film-for-treatment-of-off-periods-in-parkinson-disease/2469271/The Food and Drug Administration has approved apomorphine sublingual film (Kynmobi; Sunovion, Marlborough, MA) for the acute, intermittent treatment of “off” episodes in patients with Parkinson disease (PD). This new formulation of apomorphine provides convenient administration (placi
- AAN Practice Advisory on PFO Closure After Strokehttps://practicalneurology.com/news/aan-practice-advisory-on-pfo-closure-after-stroke/2469245/The American Academy of Neurology (AAN) has released a practice advisory concluding that poststroke surgical closure of a patent foramen ovale (PFO) may be recommended for some individuals. This practice advisory is endorsed by American Heart Association/American Stroke Association, the Society f
- Medicinal Cannabis Effective for Chronic Insomnia in Clinical Trialhttps://practicalneurology.com/news/medicinal-cannabis-effective-for-chronic-insomnia-in-clinical-trial/2469225/A randomized double-blind clinical trial evaluating the efficacy of a medicinal cannabis formulation (ZTL-101; Zelira Therapeutics Ltd, Perth, Australia) for treating chronic insomnia showed that the therapy is effective and safe. Participants treated with medicinal cannabis went
- FDA Approves Ozanimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ozanimod-for-relapsing-multiple-sclerosis/2469208/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Vazegepant Advances to Phase 3 Trials for Acute Migraine Treatmenthttps://practicalneurology.com/news/vazegepant-advances-to-phase-3-trials-for-acute-migraine-treatment/2469198/It has previously been reported that intranasal vazegepant (Biohaven Pharmaceutical, New Haven, CT) 10 mg and 20 mg achieved statistical superiority to placebo on the coprimary regulatory endpoints of pain freedom and freedom from most bothersome symptoms at 2 hours in a phase 2/3 dose-finding tr
- Alzheimer Diagnoses Increase Significantly in Adults from 2013-2017https://practicalneurology.com/news/alzheimer-diagnoses-increase-significantly-in-adults-from-2013-2017/2469175/The number of Americans diagnosed with early-onset dementia or Alzheimer disease (AD) increased by 200% from 2013 to 2017. The average age of a person living with either form of dementia is 49. The findings came from a new Blue Cross Blue Shield Association (BCBSA) report, "Early-Onset Demen
- Study Finds that Ping-Pong May Benefit People with Parkinson Diseasehttps://practicalneurology.com/news/study-finds-that-ping-pong-may-benefit-people-with-parkinson-disease/2469167/A preliminary study showed a game of ping-pong may have potential as a form of physical therapy for Parkinson’s disease (PD). Individuals with PD who participated in a ping-pong exercise program once a week for 6 months showed improvement in symptoms. In the study, parti